Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of Abraxane
(nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon
alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma.
Primary Objective:
- The primary objective of the Phase I is to determine the toxicity, safety and the
maximum tolerated dose maximum tolerated dose of Abraxane in combination with Cisplatin,
Temozolomide, interleukin-2 and interferon a2b in patients with metastatic melanoma.
Secondary Objectives:
- To assess responses to the combination.
- To evaluate the duration of response and the overall survival.
- To determine the effectiveness in delaying the appearance of Central Nervous System
disease.